List of Excipients in Branded Drug CIMETIDINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing CIMETIDINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	cimetidine hydrochloride	0121-1025	FD&C YELLOW NO. 6
PAI Holdings LLC dba PAI Pharma	cimetidine hydrochloride	0121-1025	HYDROCHLORIC ACID
PAI Holdings LLC dba PAI Pharma	cimetidine hydrochloride	0121-1025	METHYLPARABEN

What are the Most Frequently-Used Excipients in CIMETIDINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	ALCOHOL
2	FD&C RED NO. 40
4	FD&C YELLOW NO. 6

Cimetidine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 30, 2026

Cimetidine hydrochloride is a mature H2-receptor antagonist with limited composition-of-matter or exclusivity protection. Commercial value now depends on formulation execution, supply reliability, dosage-form differentiation, geographic access, and cost control. The strongest opportunities are stable oral liquids, pediatric and geriatric formulations, hospital-ready injectable products, low-cost OTC products, and global-market presentations.

What is cimetidine hydrochloride and where is it used?

Cimetidine hydrochloride is the hydrochloride salt of cimetidine, an H2-receptor antagonist that reduces gastric acid secretion. Cimetidine is used for conditions including duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, pathological hypersecretory conditions, and heartburn relief. It was historically marketed as Tagamet by SmithKline Beecham, now part of GSK.

Cimetidine was one of the first commercially successful H2 blockers. Its principal clinical limitation is a broad drug-interaction profile caused partly by inhibition of cytochrome P450 enzymes, particularly CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This has reduced its commercial position relative to famotidine and proton-pump inhibitors.

Key product characteristics

Attribute	Commercial relevance
Active ingredient	Cimetidine, commonly supplied as cimetidine hydrochloride in injectable products
Pharmacology	H2-receptor antagonist
Main dosage forms	Tablets, oral solutions or syrups, and injectable solutions
Typical strengths	200 mg, 300 mg, 400 mg, and 800 mg oral tablets; injectable strengths vary by market
Primary risks	Drug interactions, renal-dose considerations, taste, moisture sensitivity, and injectable compatibility
Patent position	Legacy protection expired; no meaningful originator exclusivity remains
Main competitors	Famotidine, omeprazole, esomeprazole, pantoprazole, lansoprazole, and antacid products

DailyMed listings show that marketed cimetidine products use different inactive-ingredient systems depending on dosage form, manufacturer, and jurisdiction (U.S. National Library of Medicine, n.d.).

What excipients are used in cimetidine hydrochloride products?

Excipient selection depends on whether the product is an immediate-release tablet, oral liquid, or sterile injectable. The hydrochloride salt can improve aqueous handling but does not by itself solve taste, moisture, compatibility, or stability problems.

Oral tablet excipients

Immediate-release cimetidine tablets typically require excipients for flow, compression, disintegration, lubrication, and film coating. Candidate systems include:

Function	Candidate excipients	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet size, density, and manufacturability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid drug release
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film former	Hypromellose, polyvinyl alcohol	Supports appearance, handling, and moisture control
Opacifier or colorant	Titanium dioxide, iron oxides, approved colorants	Product identification and light protection
Taste-control aid	Film coating, polymer barrier, sweetener in chewable systems	Reduces bitterness and improves OTC acceptability

A direct-compression formulation is commercially attractive because it reduces processing steps and supports high-volume generic production. Wet granulation can provide better content uniformity and compression behavior when the active has poor flow or when a high drug-load presentation is required.

The formulation target should be rapid and consistent immediate release rather than modified release. Cimetidine is an established immediate-release drug, and a new extended-release product would face additional clinical, regulatory, and bioequivalence complexity.

Oral liquid excipients

Oral liquids provide the clearest formulation opportunity because cimetidine is bitter and pediatric or geriatric users may have difficulty swallowing tablets. Candidate excipients include:

• Purified water as the vehicle.
• Glycerin, sorbitol, or propylene glycol as cosolvents and mouthfeel modifiers.
• Sodium citrate or citric acid for pH adjustment.
• Sodium benzoate or potassium sorbate as preservatives where permitted.
• Sucralose, saccharin sodium, or sucrose for sweetness.
• Flavor systems such as cherry, grape, or berry.
• Xanthan gum, hydroxyethyl cellulose, or other suspending agents where a suspension is used.
• Chelating agents such as disodium edetate when justified by stability data.

The preferred development path is usually a clear, ready-to-use solution if concentration, taste, and stability permit. A suspension may provide greater flexibility for dose strength but introduces sedimentation, redispersibility, microbial, and dose-uniformity requirements.

For pediatric use, excipient selection must account for age-specific exposure to ethanol, propylene glycol, benzoates, sorbitol, sucrose, and artificial sweeteners. The FDA’s inactive-ingredient framework and pediatric safety expectations should guide the formulation and labeling strategy (U.S. Food and Drug Administration, n.d.-a).

Injectable excipients

Cimetidine hydrochloride injection requires a sterile aqueous formulation with controlled pH, osmolality, particulate burden, extractables, and container compatibility. The excipient burden should remain low.

Potential components include:

• Water for Injection.
• Sodium chloride for isotonicity.
• Hydrochloric acid or sodium hydroxide for pH adjustment.
• Nitrogen overlay where oxygen control is needed.
• No preservative in single-dose presentations unless specifically justified.

An injectable product can be positioned for hospital use, emergency departments, perioperative care, and patients unable to take oral medication. The commercial barrier is higher than for tablets because the product must meet sterile manufacturing, container-closure, particulate, endotoxin, and stability requirements under applicable pharmacopeial and regulatory standards.

How should manufacturers design a cimetidine hydrochloride excipient strategy?

The most efficient strategy is to develop one robust platform for each commercial use rather than pursue a broad excipient portfolio.

Low-cost immediate-release tablets

The priority is low cost per dose, high throughput, and reliable dissolution. A direct-compression or dry-granulation platform using microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate is commercially plausible.

Key development controls include:

1. Blend uniformity across low and high tablet strengths.
2. Lubrication time, because excess magnesium stearate can slow dissolution.
3. Tablet hardness and friability.
4. Dissolution across relevant pH conditions.
5. Moisture uptake during packaging and storage.
6. Compatibility between cimetidine hydrochloride and alkaline or reactive excipients.

A film-coated tablet can improve swallowability and reduce surface exposure to moisture. For a highly price-sensitive product, coating should be justified by stability, patient acceptability, or product identification rather than cosmetic differentiation alone.

Pediatric and geriatric oral solutions

A ready-to-use oral solution can command a higher net price than a standard tablet if it solves administration problems. The main technical risks are bitterness, preservative efficacy, chemical degradation, microbial growth, and packaging accuracy.

A differentiated product could use:

• A low-sugar or sugar-free formulation.
• A calibrated oral syringe.
• A child-resistant closure.
• A concentration that reduces dosing volume without creating measurement errors.
• A pH and flavor system that limits aftertaste.
• Unit-dose cups for institutional use.

The formulation should avoid unnecessary excipients that create regulatory or safety burdens. High-viscosity systems may improve mouthfeel but can impair syringe dosing and dose recovery from the bottle.

Hospital injectable product

The commercial proposition is supply assurance, not clinical novelty. Hospitals may value:

• Ready-to-administer presentations.
• Small-volume vials.
• Premixed bags.
• Prefilled syringes where compatible with the route and stability profile.
• Clear labeling of cimetidine-equivalent strength.
• Reliable back-up supply and short lead times.

A ready-to-use injectable can support a premium over bulk vials if it reduces pharmacy preparation and medication-error risk. The development program must address compatibility with common intravenous fluids and administration sets.

What patents protect cimetidine hydrochloride products?

Cimetidine’s original composition-of-matter and basic pharmaceutical patent protection expired decades ago. The drug was introduced in the 1970s, and generic cimetidine products have been available for many years. The commercial market is therefore not protected by an active originator patent estate comparable to newer small-molecule drugs.

Legacy patent position

Patent category	Current commercial relevance
Cimetidine composition of matter	Expired
Basic therapeutic-use patents	Expired
Original tablet formulations	Expired or commercially irrelevant
Salt-form protection	Generally expired or weak for a mature known compound
New liquid or injectable formulation	Potentially patentable if technically non-obvious and clinically or manufacturing-relevant
Packaging and device claims	Potentially available, but usually narrow
Manufacturing process claims	Possible where the process improves impurity control, yield, or scale economics

A new patent filing could target a specific excipient ratio, pH range, particle-size distribution, preservative system, container, or manufacturing process. Patent strength would depend on demonstrated advantages over known cimetidine formulations. A routine substitution of one conventional excipient for another would face substantial obviousness risk.

The absence of meaningful originator exclusivity does not eliminate freedom-to-operate analysis. Current third-party patents could still cover specialized delivery devices, manufacturing processes, or combination products. A product-specific search in the relevant jurisdictions remains necessary before launch.

When does cimetidine lose exclusivity?

Cimetidine has already lost regulatory and patent exclusivity in the United States and major pharmaceutical markets. No conventional new-drug exclusivity period protects the active ingredient today.

The remaining legal controls are product-specific:

• FDA approval requirements for a new abbreviated new drug application.
• Bioequivalence requirements for immediate-release oral products.
• Sterility and chemistry, manufacturing, and controls requirements for injections.
• Labeling and safety requirements for OTC products.
• Potential pediatric or formulation exclusivity only if a new qualifying regulatory program is independently granted.
• Trademark rights for legacy brand names where still maintained.

The relevant commercial question is not loss of exclusivity but whether a new entrant can meet quality, supply, and channel requirements at a sustainable cost.

What is the FDA regulatory and Orange Book status of cimetidine?

Cimetidine products have been approved in the United States as prescription and OTC products, depending on dosage form, strength, labeling, and product sponsor. FDA Orange Book status is product-specific and can change as approvals are withdrawn, discontinued, or transferred.

For a new generic oral tablet, the likely regulatory route is an ANDA with a reference listed drug and demonstration of pharmaceutical equivalence and bioequivalence. Oral solutions may qualify for a different bioequivalence approach if the formulation meets applicable requirements and contains the same active ingredient concentration and appropriate inactive ingredients. Injectable products require sterile-product CMC data and may follow an ANDA or another abbreviated pathway depending on the reference product and presentation.

An applicant should verify:

• Current reference listed drug status.
• Whether the target strength is approved.
• Whether the dosage form is eligible for an ANDA.
• Current Orange Book patent and exclusivity listings.
• Labeling differences between prescription and OTC presentations.
• Drug-supply-chain and serialization requirements.

The Orange Book identifies approved products, therapeutic equivalence evaluations, patents, and exclusivity information but does not replace a complete patent search (U.S. Food and Drug Administration, n.d.-b).

Are Paragraph IV challenges relevant to cimetidine?

Paragraph IV litigation risk is low for the original cimetidine product because the principal patents expired long ago. A new ANDA applicant is unlikely to face a meaningful originator patent barrier for a conventional immediate-release tablet.

Paragraph IV exposure could arise if a later entrant targets:

• A newly patented liquid formulation.
• A novel injectable presentation.
• A proprietary device or delivery system.
• A combination product.
• A later-approved formulation with unexpired method-of-use or formulation claims.

For a standard generic tablet, the central risks are usually regulatory deficiencies, manufacturing cost, supply reliability, and market erosion rather than patent litigation.

What formulation patents could protect a new cimetidine product?

The most defensible formulation claims would require a measurable technical advantage. Potential targets include:

Taste-masked oral liquid

A formulation could seek protection for a defined polymer, complexation system, or multiparticulate coating that materially reduces bitterness while preserving release and stability. Claims should be tied to objective taste, dissolution, and stability results.

Stable concentrated solution

A concentrated cimetidine hydrochloride solution could have value if it reduces shipping volume or dosing volume without precipitation, discoloration, pH drift, or potency loss. The patent case would be stronger if the formulation solves a recognized concentration or storage problem.

Ready-to-use injectable

A stable premixed or prefilled presentation may be protectable through formulation and container-closure claims if it provides unexpected shelf life, reduced preparation, or compatibility advantages.

Low-impurity manufacturing process

A process that reduces specific degradants or residual solvents, improves crystallization, or lowers cost at commercial scale may support process claims. Process patents are more useful when the resulting impurity profile can be detected in the marketed product.

Which companies are challenging or competing with cimetidine?

Cimetidine competes in three groups:

Competitive group	Products	Commercial effect
H2 antagonists	Famotidine, nizatidine	Similar mechanism with different interaction and dosing profiles
Proton-pump inhibitors	Omeprazole, esomeprazole, lansoprazole, pantoprazole	Greater acid suppression and stronger long-term commercial position
OTC antacids and alginates	Calcium carbonate, magnesium hydroxide, aluminum hydroxide, alginate products	Lower-cost relief for intermittent symptoms

Famotidine is the closest pharmacological competitor. It generally has fewer clinically significant CYP-mediated drug interactions than cimetidine, which limits cimetidine’s use in patients taking multiple medicines.

Cimetidine can still compete where price, hospital familiarity, local registration, or supply availability outweighs the interaction disadvantage.

What commercial opportunities exist for cimetidine hydrochloride?

Generic oral tablets

This is the lowest-risk opportunity but also the most commoditized. Success requires:

• Low manufacturing cost.
• Multiple strengths from a common platform.
• Reliable API sourcing.
• Efficient packaging.
• Retail, institutional, and government tenders.
• Strong supply performance.

The principal revenue risk is price compression. A new entrant needs either a cost advantage or a distribution advantage.

OTC heartburn products

An OTC product can target intermittent heartburn and acid indigestion. Commercial differentiation may come from:

• Smaller pack sizes.
• Sugar-free tablets.
• Chewable formats.
• Combination with an antacid.
• Clear interaction warnings.
• Retailer-specific packaging.
• E-commerce fulfillment.

The regulatory and labeling strategy must match the applicable OTC monograph or approved labeling pathway. Cimetidine’s drug-interaction profile makes consumer labeling particularly important.

Pediatric and geriatric liquids

This segment has stronger differentiation potential than standard tablets. A product with a stable, palatable, sugar-free solution and accurate dosing device may achieve better pricing and lower direct comparability than a conventional tablet.

Hospital injectables

Injectable cimetidine is a specialized opportunity with higher technical barriers. A supplier can compete through:

• Shorter pharmacy preparation time.
• Smaller storage footprint.
• Ready-to-use formats.
• Consistent fill-finish capacity.
• Emergency inventory availability.
• Contract manufacturing and private-label supply.

Emerging and price-sensitive markets

Cimetidine remains relevant in markets where proton-pump inhibitors are more expensive, less available, or subject to prescribing restrictions. Regional opportunities depend on local registration, pharmacopoeial standards, API availability, and reimbursement.

Potential commercial regions include Latin America, parts of Asia, the Middle East, and selected African markets. Geographic expansion requires country-specific assessment of approved indications, OTC status, import controls, and local manufacturing rules.

How does cimetidine compare with famotidine and proton-pump inhibitors?

Criterion	Cimetidine	Famotidine	Proton-pump inhibitors
Mechanism	H2 receptor blockade	H2 receptor blockade	Irreversible proton-pump inhibition
Interaction burden	Relatively high	Lower than cimetidine	Product-dependent
Formulation simplicity	High for tablets; moderate for liquids	High	High for tablets, but delayed-release technology is common
Generic competition	Intense	Intense	Intense
Differentiation potential	Liquids, injectables, cost	Dosing and tolerability	Delayed release, combinations, indication breadth
Patent opportunity	Mainly formulation or process	Similar	More formulation and delivery patents historically
Commercial position	Mature and price-sensitive	Stronger H2 competitor	Larger acid-suppression market

Cimetidine has a formulation advantage in that it does not require enteric protection or delayed-release technology. That simplifies tablet development and manufacturing. Its disadvantage is clinical interaction risk and weaker physician preference in polypharmacy populations.

What generic launch risks exist?

The main generic launch risks are commercial and operational:

1. Low market value. Mature cimetidine pricing may not support a complex formulation.
2. API concentration risk. A limited supplier base can affect cost and continuity.
3. OTC channel competition. Retail buyers may favor established famotidine and proton-pump inhibitor brands.
4. Interaction-related demand erosion. Prescribers may avoid cimetidine when patients take multiple medicines.
5. Liquid stability failure. Preservative, taste, pH, or degradation problems can delay approval.
6. Injectable manufacturing cost. Sterile fill-finish economics may be unattractive without institutional contracts.
7. Regulatory mismatch. Prescription, OTC, and country-specific labeling requirements can require separate commercial programs.
8. Packaging cost. Child-resistant closures, dosing syringes, unit-dose presentations, and serialization can materially affect margins.

How strong is the patent estate for cimetidine hydrochloride?

The legacy patent estate is weak because basic exclusivity expired. A new cimetidine product can achieve defensible protection only through a narrow technical improvement supported by comparative data.

Patent strength is highest where the product demonstrates:

• Unexpected long-term stability.
• A materially improved taste profile.
• Reduced impurity formation.
• Improved dose accuracy.
• Better injectable compatibility.
• Lower manufacturing cost through a non-obvious process.
• A device or container interaction that produces measurable performance benefits.

Patent strength is low for routine excipient substitutions, conventional tablet coatings, standard sweetener changes, or ordinary packaging variations.

Key Takeaways

• Cimetidine hydrochloride is a mature, off-patent H2 antagonist with limited originator protection.
• The best commercial opportunities are oral liquids, pediatric and geriatric presentations, hospital injectables, and low-cost regional products.
• Immediate-release tablets should prioritize direct compression, rapid dissolution, moisture control, and low manufacturing cost.
• Oral liquids require careful control of bitterness, preservative efficacy, pH, chemical stability, and pediatric excipient exposure.
• Injectable products require sterile manufacturing, compatibility data, container-closure control, and a credible hospital supply proposition.
• Paragraph IV risk is low for conventional cimetidine tablets but could arise around newly patented formulations, devices, or processes.
• A new patent estate would need objective evidence of a technical advantage. Routine excipient changes are unlikely to provide strong protection.
• Famotidine and proton-pump inhibitors remain the principal competitive threats.
• Revenue potential depends more on cost, supply reliability, regulatory execution, and dosage-form differentiation than on exclusivity.

FAQs About Cimetidine Hydrochloride Formulation and Market Entry

Is cimetidine hydrochloride still commercially viable?

Yes, but mainly as a low-cost generic, hospital injectable, pediatric liquid, or regional product. Premium positioning is difficult without a clear formulation or supply advantage.

Which excipient is best for masking cimetidine bitterness?

No single excipient is universally preferred. Polymer coating, ion-complexation, high-intensity sweeteners, flavor systems, and viscosity control should be evaluated together using sensory and stability data.

Can cimetidine hydrochloride be formulated as a sugar-free oral solution?

Yes. Sugar-free systems can use sorbitol, glycerin, sucralose, saccharin sodium, flavorants, buffers, and preservatives, subject to stability, palatability, dosing, and regulatory assessment.

Is a cimetidine hydrochloride injectable protected by active patents?

The original injectable product is not generally protected by the historical cimetidine patent estate. A specific later formulation, container, process, or device could have separate patent protection.

What is the most attractive cimetidine formulation opportunity?

A stable, palatable, ready-to-use oral solution or a hospital-ready injectable generally offers more differentiation than another conventional immediate-release tablet.

References

U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

U.S. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/

United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary (USP 46-NF 41). U.S. Pharmacopeial Convention.

World Health Organization. (2020). WHO good manufacturing practices for pharmaceutical products: Main principles. World Health Organization.